Core Insights - Neurocrine Biosciences reported strong financial results for Q3 2025, with INGREZZA achieving net product sales of $687 million, reflecting a 12% year-over-year growth, while CRENESSITY generated $98 million in net product sales [1][6][13] - The company highlighted the positive impact of its products on patients and emphasized its commitment to advancing innovative therapies in neuroscience [2][4] Financial Performance - Total revenues for Q3 2025 were $794.9 million, up from $622.1 million in Q3 2024, marking a 28% year-over-year increase [4][16] - GAAP net income for Q3 2025 was $209.5 million, compared to $129.8 million in Q3 2024, with diluted earnings per share increasing from $1.24 to $2.04 [13][16] - Non-GAAP net income for Q3 2025 was $222.1 million, up from $189.2 million in Q3 2024, with diluted earnings per share rising from $1.81 to $2.17 [13][19] Product Sales Highlights - INGREZZA's net product sales for Q3 2025 were $687 million, showing a 10% sequential growth over Q2 2025 and a 12% year-over-year growth [6][8] - CRENESSITY's net product sales reached $98 million, with 540 new patient enrollment start forms, indicating strong demand and 80% reimbursement coverage for dispensed scripts [6][8] Research and Development - The company initiated a second Phase 3 registrational clinical trial for direclidine, targeting adults with schizophrenia, and presented promising data from the Phase 2 SAVITRI study for osavampator in major depressive disorder [5][6] - R&D expenses for Q3 2025 were $250 million, up from $195 million in Q3 2024, reflecting increased investment in clinical programs [4][16] Corporate Developments - Neurocrine announced the appointment of Mike Sibley as Senior Vice President and General Manager of the Neuropsychiatry franchise, aiming to enhance the sales and marketing strategy for its neuropsychiatry products [5][6] - The company plans to expand its INGREZZA and CRENESSITY sales teams to maximize commercial momentum, with completion expected by the end of Q1 2026 [5][6]

[Applause] [Applause] When I walked into that seventh grade classroom, I was carrying something a little bit weird. A homemade brainwave reading headset made from wires, tape, and a little hot glue. Most of the kids were laughing, but one skeptical 12-year-old raised his hand and asked a question.Can I try it. He slipped the headset on, watched his brain waves dance on the screen, his eyes widened, and he said something that I would never forget. If my brain runs on electricity, can I rewire it.For me, that ...

Core Idea - The presentation explores a novel approach to art creation using brainwave technology (EEG) to translate thoughts and emotions into audiovisual art in real-time [3][4][5][6][7] - The core of art should be alive, unfiltered, present, and capturing the essence of a moment in time [2] - The presenter calls this approach "full presence expression," emphasizing creation through being rather than doing [11] Technical Aspects - EEG technology captures brainwaves, which are then translated into digital signals to generate audiovisual art [5][6] - Different brainwave frequencies (beta and gamma for active thoughts, lower frequencies for calmness) correspond to different audiovisual parameters [8][9] - The system allows for a direct, raw sensory expression from the brain to the screen, akin to playing an instrument and painting simultaneously using the mind [7] Inspiration and Purpose - The project was inspired by working with underprivileged children with autism, ADHD, motor neuron disorders, and sensory impairments, who are often excluded from traditional art forms [14][15][16] - The aim is to provide a means for these individuals to express their inner voices, feelings, and emotions through art, showcasing their inner beauty and presence [17][18] - The project seeks to redefine art and expand the definition of who can be an artist, promoting connection and understanding beyond typical labels [18][20] Key Takeaway - The presentation encourages embracing inner freedom, courage, and essence to express oneself fully, unconstrained by societal norms or limitations [19][20]

Core Insights - Bristol Myers (BMY) is focusing on expanding its pipeline due to the negative impact of generics on its legacy portfolio, particularly Revlimid, Pomalyst, Sprycel, and Abraxane [1] - The FDA has granted Fast Track Designation to BMS-986446, an anti-MTBR-tau antibody in phase II development for early Alzheimer's disease [1][10] - BMY's neuroscience portfolio has been enhanced by the FDA approval of xanomeline and trospium chloride (Cobenfy) for schizophrenia, with initial sales of $62 million in the first half of 2025 [2][3] Neuroscience Pipeline - Cobenfy is undergoing registrational trials for Alzheimer's disease, including studies on psychosis, agitation, and cognitive impairment, and is also in a phase III study for bipolar 1 disorder [4] - The drug is expected to be a significant growth driver for BMY as it seeks label expansions into new indications [4] - BMY's neuroscience pipeline includes candidates for neurodegenerative diseases (BMS-986495) and treatments for multiple sclerosis, mood, and anxiety disorders [5] Competitive Landscape - BMY's Alzheimer's candidates will face competition from existing products like Eli Lilly's Kisunla and Biogen and Eisai's Leqembi upon potential approval [6] - Eli Lilly's Kisunla was approved for early symptomatic Alzheimer's disease, and ongoing trials are evaluating its efficacy in preclinical stages [7][8] Financial Performance - BMY's shares have declined by 17.1% year-to-date, contrasting with the industry's growth of 10.4% [9] - The company is trading at a price/earnings ratio of 7.24X forward earnings, below its historical mean of 8.45X and the large-cap pharma industry's average of 15.87X [11] - The bottom-line estimate for 2025 has increased to $6.51 from $6.46, while the estimate for 2026 has decreased to $6.06 from $6.07 [13]

Neuroscience of Adolescence - Adolescence is a unique window of opportunity due to increased neuroplasticity, the brain's ability to reorganize itself and form new neural connections [2][5] - During teenage years, brains are most adaptable, primed for learning and growth, but also highly susceptible to negative influences [5] - Environments directly impact brain growth, highlighting the importance of harnessing neuroplasticity to focus, adapt, and thrive [6] - Neuroscience reveals adolescence is about brains actively shaping who individuals become, with neuroplasticity at its peak [7] Enhancing Focus and Habits - Exercise and mindfulness produce brain-derived neurotrophic factor (BDNF), a protein that supports neurogenesis, the production of new neurons [8] - Neuroplasticity thrives on challenge, novelty, and even failure, as brains form new connections in uncomfortable situations [8][9] - Focus is about saying yes to the right things, activating the prefrontal cortex, the brain's CEO responsible for decision making and planning [10][11] - Small achievements release dopamine, the brain's feel-good neurotransmitter, suggesting breaking down goals into smaller, manageable tasks [12][13] - Multitasking is ineffective; the brain prefers doing one thing well, and switching between tasks leads to lost time and productivity [13][14] - Habit stacking involves pairing a new habit with an existing one to prime the brain for focus and growth [15] Influence of Environment and Social Connections - Individuals mirror the behaviors of those around them due to mirror neurons, emphasizing the importance of surrounding oneself with optimistic and supportive people [17][18] - Being intentional with what one consumes and being an inspiration for others can create a ripple effect of positive influence [19][20]

Core Argument - The document emphasizes that individual perception shapes reality, influenced by brain interpretation and filtering of experiences [1][2][3] - Neuroscience and psychology research supports the idea that altering viewpoints can foster personal growth, empathy, and social change [2] Brain Function and Perception - The brain filters information based on past experiences, leading to subjective interpretations of the same event [3][4] - The default mode network (DMN) plays a crucial role in shaping personality and understanding others' perspectives, facilitating empathy and connection [5][6][7] - Cognitive biases, such as confirmation bias and egocentric bias, can hinder objective perception [8] - Mirror neurons in the premotor cortex enable empathy by allowing individuals to experience others' feelings and actions [9] Neuroplasticity and Change - Neuroplasticity allows the brain to adapt and change, enabling individuals to modify cognitive processes and responses through deliberate practice [10][11] - Reframing situations and practicing gratitude can activate the anterior cingulate cortex, promoting emotional regulation and perspective shifts [11][12] Impact on Relationships and Society - Changing individual viewpoints can positively influence relationships by fostering compassion and reducing conflict [13] - Innovative solutions and social movements often arise from individuals who challenge traditional perspectives [13] Practical Application - Individuals should pause and consider alternative perspectives when facing problems or discussions [14]

Neuroscience and Ancient Traditions - Neuroscience validates ancient traditions like mindful meditation and acupuncture, revealing tangible brain changes [2][3][8] - Ancient approaches once considered pseudoscience are now being validated by scientific discoveries, highlighting the interconnectedness of ancient wisdom and modern technology [4][5] - Traditional Chinese Medicine (TCM) and other traditional complementary alternative medicines (TCAM) are being investigated for their validity and potential benefits [10][11] Brain Modulation and Neurotechnology - Modern technology is used to scrutinize the brain, leading to a better understanding of how to modulate thought, feeling, and sensory-motor functions [5][6] - Neurotechnologies like neurofeedback, transcranial magnetic stimulation (TMS), and brain-computer interfaces (BCI) are being used to enhance brain function and treat disabilities [14][16][17][19] - Brain mapping techniques are used to study brain wave dynamics and functional structures, revealing the unique fingerprints of individual brains [8][9] - Neural plasticity allows for reshaping and remodeling of the brain, enabling interventions to improve functionality and quality of life [14][15] Ethical Considerations in Neurotechnology - The rapid advancement of neurotechnology raises ethical concerns about privacy, confidentiality, and the potential for misuse [23][24][25] - There is a need for regulation and ethical guidelines to ensure that neurotechnology is used for the betterment of humanity [25] - Questions arise about the limits of technological intervention and the potential impact on human identity and autonomy [23][26]

[Applause] You're not actually looking at me right now. What you're seeing is your brain's best guess. Your eyes aren't windows that you're looking through.What's happening is far stranger. Your brain takes millions of sensory signals, filters them through your memories, beliefs, and expectations, and then renders its version of the external world. What you're seeing is an internal image.This is what neuroscientists call the active inference model of the brain. But here's where it gets even more strange. It ...

Core Insights - JAZZ Pharmaceuticals is a unique player in the cannabis sector, focusing on an FDA-approved drug, Epidiolex, rather than traditional cannabis cultivation or sales [1][2] - Epidiolex has become a significant growth driver for JAZZ, contributing over 25% of total product sales and showing a 5% year-over-year increase in sales [3][4] - The global medical cannabis market is projected to exceed $130 billion by 2032, providing JAZZ with a competitive advantage as one of the few established pharmaceutical firms with an FDA-approved cannabis product [5] Company Overview - JAZZ Pharmaceuticals has diversified its portfolio beyond cannabis, maintaining strong positions in neuroscience and oncology [6] - The company's neuroscience segment benefits from the oxybate franchise, particularly Xywav, which is a low-sodium treatment for narcolepsy and idiopathic hypersomnia [7] - JAZZ's oncology portfolio, including drugs like Defitelio and Vyxeos, contributed nearly 28% of product sales in the first half of 2025 [8] Recent Developments - The acquisition of Chimerix for $935 million added Modeyso, an FDA-approved drug for glioma patients, enhancing JAZZ's oncology offerings [9] - Despite setbacks in pipeline development, including the discontinuation of suvecaltamide and underwhelming results for JPZ150, JAZZ continues to explore options for its drug pipeline [10][11] Financial Performance - JAZZ's stock has increased by 5% year-to-date, outperforming the industry average of 4% [12] - EPS estimates for 2025 and 2026 have shown an upward trend, contrasting with declines in estimates for pure-play cannabis companies [13] Market Position - JAZZ Pharmaceuticals is positioned as a balanced biopharma investment, offering exposure to both neuroscience and oncology, with Epidiolex providing a unique entry into the cannabis therapeutics market [16][17]

Overview - Obvious is an art collective using AI to explore new aesthetics and the social implications of the technology [2] - The collective aims to infuse AI art into culture by collaborating with brands and institutions [4] AI Art & Technology - The collective uses self-invented algorithms to create art, sharing discoveries through scientific papers, open-source code, and artistic creations [4] - The company replicated mind-reading technology using fMRIs, generating images from brain activity [7][10] - The company devised a new protocol to capture imagination and create associated images, separating imagination into weak (memory) and strong (new image) components [14] Artistic Approach & Vision - The company draws inspiration from science and integrates it into art [4] - The company made a parallel with the surrealist movement, aiming to shorten the gap between artistic intuition and creation [17][18][19] - The company emphasizes the importance of opening a debate about mind-reading technologies through art, addressing mental privacy concerns [21] Auction Performance - In October 2018, Edmon Bami, an AI-generated artwork, was the first of its kind to be sold in a major auction house for nearly $500,000 [3]